Back

SARS-CoV-2 and Malayan pangolin coronavirus infect human endoderm, ectoderm and induced lung progenitor cells

Xiang, K.; Hong, B.; Lai, X.; Chen, Y.; Luo, T.; An, X.; Song, L.; Zhuang, H.; Fan, H.; Li, T.; Tong, Y.-G.

2020-09-25 microbiology
10.1101/2020.09.25.313270 bioRxiv
Show abstract

Since the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in several somatic cells, little is known about the infection of SASRS-CoV-2 and its related pangolin coronavirus (GX_P2V). Here we present for the first time that SARS-CoV-2 pseudovirus and GX_P2V could infect lung progenitor and even anterior foregut endoderm cells causing these cells death, which differentiated from human embryonic stem cells (hESCs). The infection and replication of SARS-CoV-2 and GX_P2V were inhibited when treated with whey protein of breastmilk and Remdesivir, confirming that these two viruses could infect lung progenitor and even anterior foregut endoderm. Moreover, we found that SARS-CoV-2 pseudovirus could infect endoderm and ectoderm. We found that whey protein blocked SARS-CoV-2 infecting these cells. In line with the SARS-CoV-2 results, GX_P2V could also infected endoderm and ectoderm, and also was inhibited by Remdesivir treatment. Although expressing coronavirus related receptor such as ACE2 and TMPRSS2, mesoderm cells are not permissive for SARS-CoV-2 and GX_P2V infection, which needed further to study the mechanisms. Interestingly, we also found that hESCs, which also express ACE2 and TMPRSS2 markers, are permissive for GX_P2V but not SARS-CoV-2 pseudovirus infection and replication, indicating the widespread cell types for GX_P2V infection. Heparin treatment blocked efficiently viral infection. These results provided insight that these stem cells maybe provided a stable repository of coronavirus function or genome. The potential consequence of SARS-CoV-2 and animal coronavirus such as GX_P2V infection in hESCs, germ layer and induced progenitors should be closely monitored.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 19%
10.1%
2
Biochemical and Biophysical Research Communications
78 papers in training set
Top 0.1%
10.1%
3
Journal of Medical Virology
137 papers in training set
Top 0.2%
7.2%
4
Journal of Virology
456 papers in training set
Top 0.9%
6.3%
5
Scientific Reports
3102 papers in training set
Top 31%
4.0%
6
Microbial Pathogenesis
13 papers in training set
Top 0.1%
4.0%
7
Emerging Microbes & Infections
74 papers in training set
Top 0.5%
2.6%
8
Journal of Molecular Cell Biology
21 papers in training set
Top 0.1%
2.1%
9
Virologica Sinica
10 papers in training set
Top 0.1%
1.9%
10
PeerJ
261 papers in training set
Top 6%
1.8%
11
Virus Research
36 papers in training set
Top 0.5%
1.7%
50% of probability mass above
12
Frontiers in Medicine
113 papers in training set
Top 4%
1.7%
13
Frontiers in Cellular and Infection Microbiology
98 papers in training set
Top 3%
1.7%
14
Biomedicines
66 papers in training set
Top 1%
1.5%
15
Gene
41 papers in training set
Top 1%
1.5%
16
Heliyon
146 papers in training set
Top 3%
1.5%
17
Frontiers in Pharmacology
100 papers in training set
Top 2%
1.5%
18
PLOS Pathogens
721 papers in training set
Top 7%
1.3%
19
Signal Transduction and Targeted Therapy
29 papers in training set
Top 0.9%
1.3%
20
Cells
232 papers in training set
Top 4%
1.2%
21
BioMed Research International
25 papers in training set
Top 2%
1.2%
22
Animals
20 papers in training set
Top 0.7%
0.9%
23
Cell Death Discovery
51 papers in training set
Top 1.0%
0.9%
24
International Journal of Molecular Sciences
453 papers in training set
Top 13%
0.9%
25
Frontiers in Microbiology
375 papers in training set
Top 8%
0.9%
26
Transboundary and Emerging Diseases
34 papers in training set
Top 0.7%
0.8%
27
Bioscience Reports
25 papers in training set
Top 1%
0.8%
28
Journal of Virological Methods
36 papers in training set
Top 0.6%
0.8%
29
F1000Research
79 papers in training set
Top 5%
0.7%
30
Frontiers in Physiology
93 papers in training set
Top 6%
0.7%